Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities

Yalan Yu, Yuzhe Pan, Shuang Peng, Wanyue Yin, Hui Shen, Jing He, Fuling Zhou

Blood (2024) 144 (Supplement 1): 3594.

https://doi.org/10.1182/blood-2024-200605

Published: 2024

Journal Articles

Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

Blood (2024) 144 (Supplement 1): 4855.

https://doi.org/10.1182/blood-2024-202870

Published: 2024

Journal Articles

An Aberrantly Overexpressed Short Isoform of TET1 Lacking a DNA Binding Domain Drives Aberrant 5-Hydroxymethylation Marks, Oncogenic Pathways, and Growth in Acute Myeloid Leukemia

Shiva Bamezai, Jing He, Pradeep Rajput, Deniz Sahin, Alex Jose Pulikkottil, Fabian Mohr, Mahalakshmi Naidu Vegi, Rana Pratap Singh, Deepshi Thakral, Ritu Gupta, Christian Buske, Vijay Pal Singh Rawat

Blood (2024) 144 (Supplement 1): 4114.

https://doi.org/10.1182/blood-2024-205890

Published: 2024

Journal Articles

Triple-Drug Regimen for Naïve MDS and AML Patients: Efficacy and Safety of Chidamide, Azacitidine, and Venetoclax in a Prospective Multicenter Study

Min Zhang, Miaomiao Zhao, Renying Ge, Xie-Na Cao, Mei Xue, Jing He, Zhaodong Zhong, Xin Fu

Blood (2024) 144 (Supplement 1): 6080.

https://doi.org/10.1182/blood-2024-204432

Published: 2024

Journal Articles

A Prospective Clinical Study of Venetoclax Plus Azacitidine for the Maintenance Treatment of Post-Remission Acute Myeloid Leukemia

Weiming Li, Fang Cheng, Jing Zou, Yuanyan Tang, Haiyan Wang, Jie Tan, Qihuan Liu, Hongbo Ren, Meifang Su, Hongxiang Wang, Zhuangzhi Yang, Lulu Zhang, Renying Ge, Jing He, Chuancai Liu, Jun Qin, Jing Zheng, Zhe Zhao

Blood (2024) 144 (Supplement 1): 2888.

https://doi.org/10.1182/blood-2024-204414

Published: 2024

Journal Articles

Patterns of Care and Resource Use Among Elderly Relapsed/Refractory Follicular Lymphoma Patients: US Medicare Claims Analysis

Savreet Bains Chawla, Shibing Yang, Jing He, Monika Jun, Nicole Heaps, Anthony Wang, Junhua Yu, Chenxue Liang, Allison Keshishian, Jon Ukropec

Blood (2023) 142 (Supplement 1): 5158.

https://doi.org/10.1182/blood-2023-181854

Published: 2023

Journal Articles

Multiplex Genome Editing of Human T Cells with Innovative Transformer Base Editor (tBE) for Construction of Next Generation CAR-T Therapies

Peixue Li, Qing Su, Ya Xu, Jing He, Lijie Wang, Yichuan Wang, Huanyu Li, Kewei Lan, Huiming Zheng, Di Zhu, Yan Zhang, Runni Guo, Hongxia Ma, Lang Zhang, Yuchen Zhang, Runze Gao, Bingbing Wu, Susan Mou, Jia Chen

Blood (2023) 142 (Supplement 1): 6825.

https://doi.org/10.1182/blood-2023-178504

Published: 2023

Journal Articles

Development of Best-in-Class Gene Editing Therapy for β-Hemoglobinopathies Using Innovative Transformer Base Editor (tBE)

Blood (2023) 142 (Supplement 1): 5243.

https://doi.org/10.1182/blood-2023-178440

Published: 2023

Journal Articles

Clinical Characteristics and Outcomes of Elderly Patients with Stage I Diffuse Large B-Cell Lymphoma: A Study By Jiangsu Cooperative Lymphoma Group (JCLG)

Blood (2023) 142 (Supplement 1): 6261.

https://doi.org/10.1182/blood-2023-181373

Published: 2023

Journal Articles

Real-World Usage of Asciminib in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) in the United States (US) Using a Large Claims Database

Sudipto Mukherjee, Chi-Chang Chen, Magdaliz Gorritz, Islam Sadek, Serban Iorga, Zifan Zhou, Jing He, Rodrigo Maegawa, Andrea Damon, Germano Ferreira, Kejal Jadhav

Blood (2022) 140 (Supplement 1): 13297–13298.

https://doi.org/10.1182/blood-2022-166473

Published: 2022

Journal Articles

Pltp Regulates BCR Signaling and Tumor Microenvironment in Diffuse Large B-Cell Lymphoma through Reprogramming of Lipid Metabolism Environment

Wenyu Shi, Qingfeng Xue, Jing He, Mingan Zhang, Jianyong Li

Blood (2022) 140 (Supplement 1): 11524.

https://doi.org/10.1182/blood-2022-165925

Published: 2022

Journal Articles

HDACi Promotes the Occurrence of Ferroptosis in CTCL

Wenyu Shi, Yuan Wang, Qingfeng Xue, Jing He, Yao Wang, Jianyong Li

Blood (2022) 140 (Supplement 1): 11572.

https://doi.org/10.1182/blood-2022-168254

Published: 2022

Journal Articles

The PARP Inhibitor Olaparib Antagonizes Leukemic Growth Induced By TET1 Overexpression in AML1-ETO Positive Acute Myeloid Leukemia

Shiva Bamezai, PhD, Jing He, Dr., Deniz Sahin, M.Sc, Fabian Mohr, PhD, Fabio Ciccarone, PhD, Naidu M Vegi, PhD, Alex Pulikkottil Jose, M.Sc, Medhanie A. Mulaw, Jun.-Prof. Dr., Paola Caiafa, MD, Konstanze Döhner, Hartmut Döhner, MD, Michaela Feuring-Buske, PD Dr., Christian Buske, Vijay P.S. Rawat, PhD

Blood (2016) 128 (22): 4063.

https://doi.org/10.1182/blood.V128.22.4063.4063

Published: 2016

Journal Articles

Deguelin Induced Differentiation of NPM1-Mutant AML In Vivo and in Vitro

Xia Zhang, MD PhD, Zichu Zhao, MD PhD, Sha Yi, MD PhD, Lu Wen, MD PhD, Jing He, MD PhD, Jingyu Hu, MD PhD, Jun Ruan, MD PhD, Jun Fang, MD PhD, Yan Chen, MD PhD

Blood (2016) 128 (22): 4030.

https://doi.org/10.1182/blood.V128.22.4030.4030

Published: 2016

Journal Articles

A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

Mark D. Minden, MD PhD, Wendy Stock, MD, Howland Crosswell, MD, Robert D Siegel, MD, Patrick Chun, MD, Steve Abella, MD, Jing He, Clarence Eng, MPH, Dan Douer, MD

Blood (2015) 126 (23): 4866.

https://doi.org/10.1182/blood.V126.23.4866.4866

Published: 2015

Journal Articles

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL)

Jeff P. Sharman, MD, Leonard M. Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Clarence Eng, MPH, Jing He, Jing Hu, PhD, Christopher A. Yasenchak, MD

Blood (2015) 126 (23): 1545.

https://doi.org/10.1182/blood.V126.23.1545.1545

Published: 2015

Journal Articles

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Jeff P. Sharman, MD, Leonard M. Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Julie Di Paolo, PhD, Clarence Eng, MPH, Jing Hu, PhD, Jing He, Anita Reddy, PhD, Christopher A. Yasenchak, MD

Blood (2015) 126 (23): 4152.

https://doi.org/10.1182/blood.V126.23.4152.4152

Published: 2015

Journal Articles

Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling

Jeff P. Sharman, MD, Andrei R. Shustov, MD, Mitchell R. Smith, MD PhD, Thomas E. Boyd, MD, Christopher Hagenstad, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Jing He, Clarence Eng, MPH, Jing Hu, PhD, Anita Reddy, PhD, Siddhartha Mitra, MDPhD, Christopher A. Yasenchak, MD, Farrukh T. Awan, MD MS

Blood (2015) 126 (23): 1744.

https://doi.org/10.1182/blood.V126.23.1744.1744

Published: 2015

Journal Articles

Low-Dose Deguelin, Selective Targeting of Mt NPM1, Induces Differentiation in NPMc+ AML Cells By Regulation the Axis of SIRT1/CEBPβ/G-CSFR, Instead of HDAC1/3

Youping Wang, Zichu Zhao, Jingyu Hu, Fei Zhao, Jing He, Jun Fang, Chun Zhang, Guohui Cui, Yan Chen

Blood (2014) 124 (21): 2231.

https://doi.org/10.1182/blood.V124.21.2231.2231

Published: 2014

Journal Articles

Deguelin, Selective Silencing of the NPM1 Mutant Protein, Induces Differentiation and Potentiates Apoptosis in Acute Myeloid Leukemia Cells Carrying NPM1 Mutation.

Sha Yi, Yan Chen, Lu Wen, Benping Zhang, Jing He, Guohui Cui, Lijing Yang, Jun Fang, Fei Zhao, Jie Zhao, Zichu Zhao

Blood (2012) 120 (21): 2435.

https://doi.org/10.1182/blood.V120.21.2435.2435

Published: 2012

NARROW

AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities

Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

An Aberrantly Overexpressed Short Isoform of TET1 Lacking a DNA Binding Domain Drives Aberrant 5-Hydroxymethylation Marks, Oncogenic Pathways, and Growth in Acute Myeloid Leukemia

Triple-Drug Regimen for Naïve MDS and AML Patients: Efficacy and Safety of Chidamide, Azacitidine, and Venetoclax in a Prospective Multicenter Study

A Prospective Clinical Study of Venetoclax Plus Azacitidine for the Maintenance Treatment of Post-Remission Acute Myeloid Leukemia

Patterns of Care and Resource Use Among Elderly Relapsed/Refractory Follicular Lymphoma Patients: US Medicare Claims Analysis

Multiplex Genome Editing of Human T Cells with Innovative Transformer Base Editor (tBE) for Construction of Next Generation CAR-T Therapies

Development of Best-in-Class Gene Editing Therapy for β-Hemoglobinopathies Using Innovative Transformer Base Editor (tBE)

Clinical Characteristics and Outcomes of Elderly Patients with Stage I Diffuse Large B-Cell Lymphoma: A Study By Jiangsu Cooperative Lymphoma Group (JCLG)

Real-World Usage of Asciminib in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) in the United States (US) Using a Large Claims Database

Pltp Regulates BCR Signaling and Tumor Microenvironment in Diffuse Large B-Cell Lymphoma through Reprogramming of Lipid Metabolism Environment

HDACi Promotes the Occurrence of Ferroptosis in CTCL

The PARP Inhibitor Olaparib Antagonizes Leukemic Growth Induced By TET1 Overexpression in AML1-ETO Positive Acute Myeloid Leukemia

Deguelin Induced Differentiation of NPM1-Mutant AML In Vivo and in Vitro

A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL)

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling

Low-Dose Deguelin, Selective Targeting of Mt NPM1, Induces Differentiation in NPMc+ AML Cells By Regulation the Axis of SIRT1/CEBPβ/G-CSFR, Instead of HDAC1/3

Deguelin, Selective Silencing of the NPM1 Mutant Protein, Induces Differentiation and Potentiates Apoptosis in Acute Myeloid Leukemia Cells Carrying NPM1 Mutation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only